Events DC Implements Synexis BioDefense System to Improve Indoor Air Quality at Walter E. Washington Convention Center
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
The FDA has authorized the use of REGEN-COV (casirivimab and imdevimab) for post-exposure prophylaxis of COVID-19.
Credit: Regeneron. The Food and Drug Administration (FDA) has authorized the use of REGEN-COV (casirivimab and imdevimab) for postexposure prophylaxis of COVID-19 in individuals (12 years of age and older weighing at least 40kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. The investigational agent was previously granted Emergency Use Authorization (EUA) for the treatment of mild to moderate COVID-19. REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS...
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Phase
COVID-19 and the resulting economic crisis have highlighted and exacerbated the plight of American farmers, while also threatening already